Literature DB >> 22192978

High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.

Zhe Zhang1, Guojun Zhang, Chuize Kong.   

Abstract

OBJECTIVES: Polo-like kinase 1 (Plk1) has been widely pursued as an oncology target because it is overexpressed in several human tumor types. To investigate whether Plk1 plays a general role in bladder urothelial carcinoma, we examined the expression of Plk1 protein in bladder urothelial carcinoma and cell lines, and analyzed the relationship among Plk1 protein expression, metastasis, and recurrence of urinary bladder urothelial carcinoma.
METHODS: Immunohistochemistry was used to detect the expression of Plk1 in 120 bladder urothelial carcinoma. Moreover, the expression of Plk1 was analyzed by Western blot in 60 bladder urothelial carcinoma and 21 normal epithelial tissues. MTT assay and flow cytometry and transwell assay were used to examine the proliferative and invasive ability of bladder cancer cells with the treatment of scytonemin (the inhibitor of Plk1). Statistical analysis was used to discuss the association between Plk1 expression and clinicopathologic parameters, tumor metastasis and recurrence, and the proliferative and invasive ability and cell cycle process of the bladder cancer cells.
RESULTS: There was a significantly higher Plk1expressions in bladder urothelial carcinoma and highly invasive bladder T24 cells than those in bladder normal tissues and the superficial bladder BIU-87 cells. Plk1 expression was positively correlated with histologic grade, pT stage, recurrence, and metastasis. With the increasing concentration of scytonemin, we found that not only the cell proliferation and invasion activity decreased significantly, but also the cell cycle was blocked at G2/M stage.
CONCLUSION: Plk1 expression status was closely correlated with important histopathologic characteristics (grades and stages) and the recurrence and metastasis of bladder urothelial carcinomas. Furthermore, Plk1 played an important function on the bladder cancer cells' proliferation by regulating the cancer cell cycle from G1/S to G2/M and probably promoted the invasion and metastasis of bladder cancer.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bladder urothelial carcinoma; Clinical stage; Histopathologic grade; Polo-like kinase 1; Scytonemin

Mesh:

Substances:

Year:  2011        PMID: 22192978     DOI: 10.1016/j.urolonc.2011.11.028

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  30 in total

1.  Plk1 promotes the migration of human lung adenocarcinoma epithelial cells via STAT3 signaling.

Authors:  Weijuan Yan; Huijie Yu; Wei Li; Fengsheng Li; Sinian Wang; Nan Yu; Qisheng Jiang
Journal:  Oncol Lett       Date:  2018-09-14       Impact factor: 2.967

2.  A long non-coding RNA signature to improve prognosis prediction of gastric cancer.

Authors:  Xiaoqiang Zhu; Xianglong Tian; Chenyang Yu; Chaoqin Shen; Tingting Yan; Jie Hong; Zheng Wang; Jing-Yuan Fang; Haoyan Chen
Journal:  Mol Cancer       Date:  2016-09-20       Impact factor: 27.401

3.  In vitro targeting of Polo-like kinase 1 in bladder carcinoma: comparative effects of four potent inhibitors.

Authors:  María Sol Brassesco; Julia Alejandra Pezuk; Andressa Gois Morales; Jaqueline Carvalho de Oliveira; Gabriela Molinari Roberto; Glenda Nicioli da Silva; Harley Francisco de Oliveira; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  Cancer Biol Ther       Date:  2013-05-31       Impact factor: 4.742

4.  High FOXM1 expression was associated with bladder carcinogenesis.

Authors:  Dongye Liu; Zhe Zhang; Chui-ze Kong
Journal:  Tumour Biol       Date:  2013-01-17

5.  Scytonemin inhibits cell proliferation and arrests cell cycle through downregulating Plk1 activity in multiple myeloma cells.

Authors:  Guojun Zhang; Zhe Zhang; Zhuogang Liu
Journal:  Tumour Biol       Date:  2013-04-13

6.  Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells.

Authors:  Guojun Zhang; Zhe Zhang; Zhuogang Liu
Journal:  Tumour Biol       Date:  2013-03-14

7.  PLK-1 Expression is Associated with Histopathological Response to Neoadjuvant Therapy of Hepatic Metastasis of Colorectal Carcinoma.

Authors:  M J Fernández-Aceñero; D Cortés; T Gómez del Pulgar; A Cebrián; L Estrada; J Martínez-Useros; A Celdrán; J García-Foncillas; C Pastor
Journal:  Pathol Oncol Res       Date:  2015-11-17       Impact factor: 3.201

8.  High expression of Cdc25B and low expression of 14-3-3σ is associated with the development and poor prognosis in urothelial carcinoma of bladder.

Authors:  Zhe Zhang; Guojun Zhang; Chuize Kong
Journal:  Tumour Biol       Date:  2014-03

9.  Down-regulation of the ErbB3 binding protein 1 in human bladder cancer promotes tumor progression and cell proliferation.

Authors:  Hui-chan He; Xiao-hui Ling; Jian-guo Zhu; Xin Fu; Zhao-dong Han; Yu-xian Liang; Ye-han Deng; Zhuo-yuan Lin; Guo Chen; Yan-fei Chen; Ru-jun Mo; Wei-de Zhong
Journal:  Mol Biol Rep       Date:  2013-01-03       Impact factor: 2.316

Review 10.  Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications.

Authors:  Ion Cristóbal; Federico Rojo; Juan Madoz-Gúrpide; Jesús García-Foncillas
Journal:  Mol Cell Biol       Date:  2016-05-31       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.